BRIEF—Opthea decides to discontinue wet AMD trials

Following the negative results of theCOAST Phase III trial announced on 24 March, Australia-based Opthea announced has updated on its clinical program, including the termination of COAST (Combination of OPT-302 with Aflibercept Study) and accelerated top-line results from its second Phase III trial ShORe (Study of OPT-302 in combination with Ranibizumab) in patients with wet AMD.

“We are disappointed that COAST and ShORe did not demonstrate the improvements in vision with sozinibercept combination therapy compared to standard of care that we had hoped for,” said Frederic Guerard, PharmD, chief executive of Opthea.

“We are grateful to all patients, clinical investigators and their staff around the world who participated in the sozinibercept Phase III clinical program, and for their contributions in investigating new treatments for wet AMD,” he added.